FDA Says Ozempic Stays Safe: Generics Can Join the Party
Published Date: 4/30/2026
Notice
Summary
The FDA has confirmed that OZEMPIC (semaglutide) 2 mg/1.5 mL wasn’t taken off the market because of safety or effectiveness problems. This means generic drug makers can keep applying to sell their versions, and the FDA will keep approving them if they meet the rules. Patients and pharmacies can keep trusting OZEMPIC without worries about sudden changes or price spikes.
Analyzed Economic Effects
2 provisions identified: 2 benefits, 0 costs, 0 mixed.
Generic Makers Can Keep Filing ANDAs
The FDA determined OZEMPIC (semaglutide) solution, 2 mg/1.5 mL, was not withdrawn for reasons of safety or effectiveness. That means companies can continue to submit abbreviated new drug applications (ANDAs) that refer to this product (NDA 209637, originally approved December 5, 2017), and the FDA will continue to approve those ANDAs if they meet all legal and regulatory requirements.
Patients and Pharmacies Reassured
The FDA found OZEMPIC (semaglutide) 2 mg/1.5 mL was not withdrawn for safety or effectiveness, so patients and pharmacies can rely on the product's status and should not expect sudden regulatory removal for safety/effectiveness reasons. The notice affirms continuity of the product's listing (in the Orange Book "Discontinued Drug Product List") and signals no immediate regulatory reason for sudden supply changes or price spikes tied to safety/effectiveness withdrawal.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-09767 — Oscar Bobo: Final Debarment Order
Oscar Bobo is officially banned for 5 years from importing any drugs into the U.S. because he repeatedly brought in mislabeled medicines that don’t follow FDA rules. He didn’t respond to the FDA’s warning, so the ban started on May 15, 2026. If he wants to end the ban early, he can apply anytime, but must follow special rules to keep his info private.
2026-09533 — Biomarker Incubator: Urinary Kidney Safety Biomarkers; Request for Information
The FDA wants your help to improve tests that spot kidney damage caused by medicines. They’re asking researchers, doctors, and companies to share data by July 13, 2026, so they can make these kidney safety markers better and faster. This could lead to safer drugs and smarter health checks, benefiting patients and the medical community alike.
2026-09508 — Azodicarbonamide (ADA); Request for Information
The FDA is asking for info about azodicarbonamide (ADA), a chemical used in some foods and food packaging, to check if it’s still safe. Food makers, scientists, and anyone with data should share what they know by July 13, 2026. This review could lead to changes in how ADA is used, affecting food companies and possibly costs down the line.
2026-09543 — Agency Information Collection Activities; Proposed Collection; Comment Request; Postmarketing Adverse Experience Reporting
The FDA wants your thoughts on how drug companies report problems after their products hit the market. This update affects drug makers and helps keep medicine safe by improving how side effects are tracked. You’ve got until July 13, 2026, to share your comments—no cost to join, just your voice!
2026-09544 — Modified Risk Tobacco Product Application: Renewal Applications for VLN® King and VLN® Menthol King, Cigarette Products Submitted by 22nd Century Group Inc.
The FDA is inviting the public to comment on the renewal of special approval for two cigarette products by 22nd Century Group Inc. These products claim to lower health risks compared to regular cigarettes. If renewed, the company can keep marketing them this way, with the comment period starting May 13, 2026.
2026-09507 — Butylated Hydroxytoluene (BHT); Request for Information
The FDA wants to know more about how butylated hydroxytoluene (BHT), a chemical used in food and food packaging, is being used and if it’s still safe. They’re asking companies, scientists, and the public to share any info by July 13, 2026. This could lead to changes in rules that affect food makers and might impact what’s allowed in your snacks and packaging.
Previous / Next Documents
Previous: 2026-08434 — GCM Grosvenor Private Equity Capital Opportunities Fund and GCM Grosvenor Wealth L.P.
GCM Grosvenor’s Private Equity Capital Opportunities Fund and Wealth L.P. want permission to pay their investment advisors with company shares instead of cash. This change could affect investors and advisors by mixing up how fees are handled, starting soon unless someone asks for a hearing by May 26, 2026. It’s a fresh twist on fees that might impact how money flows in these funds.
Next: 2026-08436 — Agency Information Collection Activities; Submission to the Office of Management and Budget for Review and Approval; Comment Request; U.S. Department of Education Supplemental Information for the SF-424 Form
The Department of Education wants to keep collecting extra info on the SF-424 form from state, local, and tribal governments without changing anything. They’re asking for public comments by June 1, 2026, to make sure the process stays smooth and not too time-consuming. This extension won’t cost extra but helps the Department keep doing its job well.